FUNDING & OPPORTUNITIES
The Milner Therapeutics Institute is part of the School of Biological Sciences and the School of Clinical Medicine at the University of Cambridge, and is dedicated to the conversion of ground breaking science into therapies. Based on the Cambridge Biomedical Campus, the institute is surrounded by a global therapeutic alliance of 74 SMEs, pharma companies, academic institutions and venture capital firms.
We periodically run calls that offer physical space for startup companies, as well as opportunities for funding and collaboration. Please see below for a list of our current opportunities.
The Milner Therapeutics Consortium is excited to announce its second call for research proposals.
The call is now open, and will close for applications on 30th March 2022.
Our pharma partners in the Milner Therapeutics Consortium are working together with academics at the University, Babraham and Wellcome Sanger Institutes to better understand disease mechanisms and to discover and validate new therapeutic targets. These pre-clinical projects range from reagent sharing and 6-month pilots to 2-year postdoctoral funded collaborations and are expected to lead to joint publications with the company partners.
Do you have an idea for a potential pre-clinical collaborative project that would benefit from industry expertise and know-how?
For more details click here.
Are you a start-up interested in bio-incubator space?
We currently have a unique opportunity for you to be part of a vibrant Institute in a much sought after location on Cambridge Biomedical Campus. The Milner Therapeutics Institute has limited space for research intensive, R&D companies, working in an areas related to the Institute’s expertise (e.g. functional genomics, early target discovery, therapeutics). You will be working side by side with academics, entrepreneurs and industry scientists.